Molecular Biomarker Revolution in Metastatic NSCLC
During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC. Participants will learn how to integrate next generation sequencing (NGS) into their biomarker testing workflows and optimize its use for patients. Finally, faculty share best practices in biomarker testing, reporting, and communication to help pathologists and laboratory professionals guide medical oncologists and other team members in the appropriate diagnosis, testing, and treatment for patients. This activity offers 1.0 CME/CMLE credit. Register for the online course here: https://store.ascp.org/productlisting.... Funded by an independent educational grant from AstraZeneca Pharmaceuticals.
Molecular testing in lung cancer explained in 1 slide by a thoracic pathologist
Small Cell Lung Cancer/ Small Cell Carcinoma
Advanced NSCLC: Advances in Biomarker Testing and Immunotherapy
The French Do Not Care About Work
Ivermectin to Treat Cancer? Get the FACTS
'CANCER OCCURRED near injection sites...': Bombshell testimony ‘EXPOSES’ COVID-19 vaccine injuries
Fighting Misinformation in the Public Sphere
The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking NewTreatment Opportunities
#PULMPATH Non-Small Cell Carcinoma, Pitfalls and Mimics
Biomarker Testing Changed Everything: MET Amplification in My Lung Cancer | Amy’s Story (2 of 3)
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
International Lab Scientist Practicing in the US
'All of them took BOOSTERS': Witness’ explosive claim linking mRNA COVID vaccines to cancer relapse
Cancer Metabolism: From molecules to medicine
Lung Cancer Staging - Tumor (T)
Before you Start or Refuse Cancer Therapy- WATCH THIS!
Making the Lab’s Value Heard in the C-Suite
12. Introduction into molecular methods in cancer diagnosis - Dr Matthew Clarke
Understanding Biomarker Testing in Non-Small Cell Lung Cancer
